BET inhibition decreases HMGCS2 and sensitizes resistant pancreatic tumors to gemcitabine
Aubrey L. Miller, Samuel C. Fehling, Rebecca B. Vance, Dongquan Chen, Eric Josh Brown, Md. Iqbal Hossain, Eric O. Heard, Shaida A. Andrabi, Hengbin Wang, Eddy S. Yang, Donald J. Buchsbaum, Robert C.A.M. van Waardenburg, Susan L. Bellis, Karina J. Yoon
Topics & Concepts
GemcitabineIn vivoCancer researchBiologyPancreatic cancerDownregulation and upregulationAdenocarcinomaIn vitroCancerBiochemistryGeneGeneticsProtein Degradation and InhibitorsCancer-related gene regulationUbiquitin and proteasome pathways